Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

1.

Ivabradine in stable coronary artery disease without clinical heart failure.

Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators.

N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430. Epub 2014 Aug 31.

2.

Effect of a telemonitoring-facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA-HF 1 (TElemonitoring in the MAnagement of Heart Failure) study.

Dendale P, De Keulenaer G, Troisfontaines P, Weytjens C, Mullens W, Elegeert I, Ector B, Houbrechts M, Willekens K, Hansen D.

Eur J Heart Fail. 2012 Mar;14(3):333-40. doi: 10.1093/eurjhf/hfr144. Epub 2011 Nov 1.

PMID:
22045925
3.

Therapeutic education in patients with chronic heart failure: proposal for a multiprofessional structured programme, by a French Task Force under the auspices of the French Society of Cardiology.

Jourdain P, Juillière Y; Steering and Working Group Committee Members of the French Task Force on Therapeutic Education in Heart Failure.

Arch Cardiovasc Dis. 2011 Mar;104(3):189-201. No abstract available.

PMID:
21634217
4.

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators.

Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010 Dec 11;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadán, I Roldan]; Leva, M [corrected to Ieva, M].

PMID:
20801500
5.

Eco-, geno- and human toxicology of bio-active nanoparticles for biomedical applications.

Robbens J, Vanparys C, Nobels I, Blust R, Van Hoecke K, Janssen C, De Schamphelaere K, Roland K, Blanchard G, Silvestre F, Gillardin V, Kestemont P, Anthonissen R, Toussaint O, Vankoningsloo S, Saout C, Alfaro-Moreno E, Hoet P, Gonzalez L, Dubruel P, Troisfontaines P.

Toxicology. 2010 Mar 10;269(2-3):170-81. doi: 10.1016/j.tox.2009.11.002. Epub 2009 Nov 26.

PMID:
19944128
6.

Type III secretion: more systems than you think.

Troisfontaines P, Cornelis GR.

Physiology (Bethesda). 2005 Oct;20:326-39. Review.

7.

[Clinical case of the month. Precordialgia evoking a coronary instability syndrome, a diagnostic danger].

Gach O, Troisfontaines P, Legrand V.

Rev Med Liege. 2003 Oct;58(10):611-4. French.

PMID:
14677519
8.

Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction.

Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA.

Circulation. 2003 Oct 7;108(14):1713-7. Epub 2003 Sep 15.

9.

[Image of the month. Isolated single coronary artery or blockage of the common arterial trunk and branches? ].

Gach O, Troisfontaines P, Legrand V.

Rev Med Liege. 2003 Mar;58(3):117-8. French. No abstract available.

PMID:
12723503
10.

Identification of substrates and chaperone from the Yersinia enterocolitica 1B Ysa type III secretion system.

Foultier B, Troisfontaines P, Vertommen D, Marenne MN, Rider M, Parsot C, Cornelis GR.

Infect Immun. 2003 Jan;71(1):242-53.

11.

Characterization of the ysa pathogenicity locus in the chromosome of Yersinia enterocolitica and phylogeny analysis of type III secretion systems.

Foultier B, Troisfontaines P, Müller S, Opperdoes FR, Cornelis GR.

J Mol Evol. 2002 Jul;55(1):37-51.

PMID:
12165841
12.

Effect of low- and high-virulence Yersinia enterocolitica strains on the inflammatory response of human umbilical vein endothelial cells.

Denecker G, Tötemeyer S, Mota LJ, Troisfontaines P, Lambermont I, Youta C, Stainier I, Ackermann M, Cornelis GR.

Infect Immun. 2002 Jul;70(7):3510-20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk